Cargando…

Chk-mate on resistance to kinase inhibitors

Detalles Bibliográficos
Autor principal:	Shapiro, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	News
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114960/ https://www.ncbi.nlm.nih.gov/pubmed/30167074 http://dx.doi.org/10.18632/oncotarget.25802

Ejemplares similares

Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma
por: Black, Elizabeth M., et al.
Publicado: (2022)

Targeting Chk1 in the replicative stress response
por: Dai, Yun, et al.
Publicado: (2010)

Rho-Associated Kinase Inhibitors: Potential Future Treatments for Glaucoma
por: Daneshvar, Ramin, et al.
Publicado: (2014)

Cell cycle keeps Fus2p in check before yeast mate
por: Short, Ben
Publicado: (2009)

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer
por: Nair, Jayakumar, et al.
Publicado: (2020)

Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation
por: Yu, Xinfang, et al.
Publicado: (2020)

Chk1, Chk2, is the amplifier on?
por: Dove, Alan W.
Publicado: (2001)

Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity
por: Massey, Andrew J.
Publicado: (2016)

The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor
por: Liang, Xiaobing, et al.
Publicado: (2011)

T315I(+) tyrosine-kinase independent CML cells resistance
por: Nicolini, Franck Emmanuel, et al.
Publicado: (2017)

CHK2 kinase in the DNA damage response and beyond
por: Zannini, Laura, et al.
Publicado: (2014)

High-Content Screening of Eukaryotic Kinase Inhibitors Identify CHK2 Inhibitor Activity Against Mycobacterium tuberculosis
por: Shapira, Tirosh, et al.
Publicado: (2020)

CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin
por: Di Franco, Simone, et al.
Publicado: (2021)

Check Mate! The CERN vs Fermilab Chess Competition
Publicado: (2001)

Phosphoglycerate Mutase Cooperates with Chk1 Kinase to Regulate Glycolysis
por: Mikawa, Takumi, et al.
Publicado: (2020)

AR phosphorylation and CHK2 kinase activity regulates IR-stabilized AR–CHK2 interaction and prostate cancer survival
por: Ta, Huy Q, et al.
Publicado: (2020)

In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors
por: Uddin, Muhammad Erfan, et al.
Publicado: (2021)

Dominant mutations in CHK1 cause pronuclear fusion failure and zygote arrest that can be rescued by CHK1 inhibitor
por: Zhang, Honghui, et al.
Publicado: (2021)

BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1
por: Li, Lemin, et al.
Publicado: (2023)

Csk-homologous kinase (Chk) is an efficient inhibitor of Src-family kinases but a poor catalyst of phosphorylation of their C-terminal regulatory tyrosine
por: Advani, Gahana, et al.
Publicado: (2017)

MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity
por: Branigan, Timothy B., et al.
Publicado: (2021)

Division of labor of the replication fork protection complex subunits in sister chromatid cohesion and Chk1 activation
por: Noguchi, Eishi
Publicado: (2011)

γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
por: Rawlinson, Rebecca, et al.
Publicado: (2014)

A hairy kinase
por: LeBrasseur, Nicole
Publicado: (2005)

An adhesion kinase on centrosomes
por: LeBrasseur, Nicole
Publicado: (2008)

Kinases KISS and tell
por: Short, Ben
Publicado: (2015)

EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer
por: Lee, Kevin J., et al.
Publicado: (2020)

Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway
por: Hunter, Jill E., et al.
Publicado: (2022)

Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1
por: Omote, Saki, et al.
Publicado: (2018)

MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells
por: Bridges, Kathleen A., et al.
Publicado: (2016)

Tony Hunter: Kinase king
por: Williams, Ruth
Publicado: (2008)

How kinases dodge trouble
por: Leslie, Mitch
Publicado: (2007)

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
por: Rorà, Andrea Ghelli Luserna Di, et al.
Publicado: (2016)

Regulation of Chk1
por: Tapia-Alveal, Claudia, et al.
Publicado: (2009)

A phospho-proteomic screen identifies substrates of the checkpoint kinase Chk1
por: Blasius, Melanie, et al.
Publicado: (2011)

Interdependent Phosphorylation within the Kinase Domain T-loop Regulates CHK2 Activity
por: Guo, Xin, et al.
Publicado: (2010)

CK1δ Kinase Activity Is Modulated by Chk1-Mediated Phosphorylation
por: Bischof, Joachim, et al.
Publicado: (2013)

Kinase-independent role for CRAF-driving tumour radioresistance via CHK2
por: Advani, Sunil J., et al.
Publicado: (2015)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2015)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7its2gnnn0nc1i1am6k34ap5m4